ESTRO 2024 - Abstract Book

S394

Brachytherapy - Urology

ESTRO 2024

Conclusion:

Permanent prostate brachytherapy monotherapy with I-125 demonstrated excellent long-term outcomes in this large patient series, with a 20-year FFBF rate of 69%. Biochemical relapse was associated with higher pre-treatment PSA levels and intermediate risk. Late grade 3 GU and GI toxicities at 20 years were 18% and 2%, respectively.

Keywords: prostate cancer, iodine-seed, low-dose-rate